• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Johns Hopkins Arthritis Center

Show Search
Hide Search
  • Disease Information
    • Rheumatoid Arthritis
    • Psoriatic Arthritis
    • Ankylosing Spondylitis
    • Osteoarthritis
    • Gout
    • Osteoporosis
  • Patient Corner
    • Drug Information Sheets
    • Managing Your Arthritis
    • RheumTV – Patient Education Video Library
  • Our Research
    • Patient-Centered Outcomes Research
    • Current Research Studies
    • The Camille Julia Morgan Arthritis Research and Education Fund
  • About Us
    • Appointment Information
    • Contact Us
    • Our Faculty
    • Our Staff
    • Rheumatology Specialty Centers
    • News & Updates
  • Donate
Home / Patient Corner / Drug Information Sheets / Infliximab (Remicade®)

Infliximab (Remicade®)

What is Infliximab (Remicade®)?

Infliximab is used to reduce signs and symptoms of rheumatoid arthritis, such as joint swelling, pain, tiredness, and duration of morning stiffness. The brand name for Infliximab is Remicade®. You will also take Methotrexate while on Infliximab.

How do I take it?

Infliximab is an infusion (intravenous medication). After you receive your first dose you will get your second dose 2 weeks later and the third dose 4 weeks after the second dose. The maintenance dose begins after the third dose. The infusion for maintenance is every 8 weeks.

What else should I know?

Infliximab works quickly. Patients, who respond to infliximab, generally feel better within 2 weeks of starting therapy. The infusion usually takes about 2 hours. Occasionally patients have a reaction to the infusion. These reactions are usually treated with Tylenol or Benadryl. Blood work will be done every 4-8 weeks to check your liver function since you will still be on Methotrexate.

Notify your doctor if you have any signs or symptoms of a serious infection, such as high fever, pneumonia, sinus infection or kidney infection.

What about other medications?

When you are taking Infliximab, it is very important that your doctors know if you are taking any other medicine. This includes prescription and non-prescription medicines as well as birth control pills, vitamins, and herbal supplements.

Infliximab will be taken with methotrexate. Your doctor will advise you on other medications.

Receive the Latest News from Johns Hopkins Rheumatology

Receive the Latest News from Johns Hopkins Rheumatology

Join our mailing list to receive the latest news and updates from Johns Hopkins Rheumatology.

Interested In

You have Successfully Subscribed!

Use of this Site

All information contained within the Johns Hopkins Arthritis Center website is intended for educational purposes only. Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained within this site. Consumers should never disregard medical advice or delay in seeking it because of something they may have read on this website.

Primary Sidebar

Disease Information

  • Rheumatoid Arthritis
  • Psoriatic Arthritis
  • Ankylosing Spondylitis
  • Osteoarthritis
  • Gout
  • Osteoporosis

Support Research at the Johns Hopkins Arthritis Center

  • Johns Hopkins Rheumatology
  • Arthritis Center
  • Lupus Center
  • Lyme Disease Clinical Research Center
  • Myositis Center
  • Scleroderma Center
  • Sjogren’s Syndrome Center
  • Vasculitis Center
RheumTV Logo

Rheum.TV is an informational platform created to educate patients living with a rheumatic disease. With over 100 disease education videos produced by the team at Johns Hopkins Rheumatology.

Visit Rheum.TV

Footer

Johns Hopkins Rheumatology

  • Johns Hopkins Rheumatology
  • Johns Hopkins Lupus Center
  • Johns Hopkins Lyme Disease Research Center
  • Johns Hopkins Myositis Center
  • Johns Hopkins Scleroderma Center
  • Johns Hopkins Sjögren’s Syndrome Center
  • Johns Hopkins Vasculitis Center

Connect With Us

  • Facebook
  • Twitter
  • YouTube

Johns Hopkins Medicine

© 2025 Johns Hopkins Arthritis Center
Patient Privacy